Compare ACCL & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACCL | GLTO |
|---|---|---|
| Founded | 2009 | 2011 |
| Country | Hong Kong | Denmark |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.8M | 54.5M |
| IPO Year | 2025 | 2020 |
| Metric | ACCL | GLTO |
|---|---|---|
| Price | $3.10 | $20.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $36.00 |
| AVG Volume (30 Days) | 82.0K | ★ 92.0K |
| Earning Date | 02-20-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2.91 | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $4,888,824.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $35.11 | ★ N/A |
| Revenue Growth | ★ 11.91 | N/A |
| 52 Week Low | $2.10 | $2.01 |
| 52 Week High | $5.00 | $38.33 |
| Indicator | ACCL | GLTO |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 44.10 |
| Support Level | N/A | $21.56 |
| Resistance Level | N/A | $38.33 |
| Average True Range (ATR) | 0.00 | 3.98 |
| MACD | 0.00 | -1.46 |
| Stochastic Oscillator | 0.00 | 4.74 |
Acco Group Holdings Ltd is a holding company. Through its Operating Subsidiaries, it is a multi-disciplinary, IT-driven corporate service provider with a presence in Hong Kong and Singapore. Under the Accolade brand, it specializes in offering corporate secretarial services and accounting services in Hong Kong, as well as intellectual properties (IP) registration services in Singapore. Leveraging developed IT solutions, It provides comprehensive, reliable and professional support to its clients, enabling them to focus on their core business activities while it manages and handles their corporate compliance needs. Its clientele ranges from individual clients, small and medium-sized enterprises to multinational corporations, reflecting its ability to cater to diverse business needs.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.